- Home
- SEER vs DTIL Comparison
SEER vs DTIL Comparison
Compare SEER & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | DTIL |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 123.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SEER | DTIL |
|---|---|---|
| Price | $1.83 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 156.8K | ★ 227.5K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,376,999.00 | $698,000.00 |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $3.61 |
| 52 Week High | $2.59 | $8.82 |
Technical Indicators
Market Signals| Indicator | SEER | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 39.42 |
| Support Level | $1.85 | $4.70 |
| Resistance Level | $2.02 | $5.20 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 7.32 | 27.03 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.